Abstract
New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%) http://bit.ly/2yJyUVT
Publication types
-
Clinical Trial, Phase III
-
Letter
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Age Factors
-
Aged
-
Aged, 80 and over
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Double-Blind Method
-
Dyspnea / drug therapy*
-
Dyspnea / physiopathology
-
Female
-
Humans
-
Idiopathic Pulmonary Fibrosis / drug therapy*
-
Male
-
Middle Aged
-
Pyridones / therapeutic use*
-
Quality of Life
-
Severity of Illness Index
-
Sex Factors
-
Surveys and Questionnaires
-
Time Factors
-
Treatment Outcome
-
Vital Capacity
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Pyridones
-
pirfenidone